Advertisement

Intrathecal baclofen in current neuromodulatory practice: established indications and emerging applications

  • I. G. Panourias
  • M. Themistocleous
  • Damianos E. Sakas
Part of the Acta Neurochirurgica Supplements book series (NEUROCHIRURGICA, volume 97/1)

Summary

Intrathecal baclofen (ITB) has evolved into a standard treatment for severe spasticity of both spinal and cerebral origin. The accumulated promising data from reported series of patients receiving ITB therapy together with the fact that spastic hypertonia commonly coexists with other neurological disorders have constituted a solid basis for offering this kind of treatment to patients suffering from other movement disorders. These include motor disorders such as dystonia, amyotrophic lateral sclerosis, status dystonicus, Hallervorden-Spatz disease, Freidreich’s ataxia, “stiff-man” syndrome, but also vegetative states after severe brain trauma, anoxic encephalopathy or other pathology and more recently, various chronic pain syndromes. In this article, on the basis of the established applications of ITB therapy, we review the important emerging indications of this rewarding neuromodulation method and attempt to identify its future potential beneficial role in other chronic and otherwise refractory neurological disorders.

Keywords

Neuromodulation spasticity hypertonia pain intrathecal baclofen therapy spinal injury head injury multiple sclerosis cerebral palsy vegetative state 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Albright AL, Cervi A, Singletary J (1991) Intrathecal baclofen for spasticity in cerebral palsy. JAMA 265: 1418–1422PubMedCrossRefGoogle Scholar
  2. 2.
    Albright LA, Barron WB, Fasick MP, Polinko P, Janosky J (1993) Continuous intrathecal baclofen infusion for infusion for spasticity of cerebral origin. JAMA 270: 2475–2478PubMedCrossRefGoogle Scholar
  3. 3.
    Albright AL, Barry MJ, Shafron DH, Ferson SS (2001) Intrathecal baclofen for generalized dystonia. Dev Med Child Neurol 43: 652–657PubMedCrossRefGoogle Scholar
  4. 4.
    Albright AL, Gilmartin R, Swift D, Krach LE, Ivanhoe CB, McLaughin JF (2003) Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg 98: 291–295PubMedGoogle Scholar
  5. 5.
    Amano M, Kubo T (1993) Involvement of both GABA A and GABA B receptors in tonic inhibitory control of blood pressure at the rostral ventrolateral medulla of the rat. Naunyn-Schmiedeberg’s Arch Pharmacol 348: 146–153CrossRefGoogle Scholar
  6. 6.
    Armstrong RW, Steinbok P, Cochrane DD, Kube SD, Fife SE, Farrel K (1997) Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin. J Neurosurg 87: 409–414PubMedGoogle Scholar
  7. 7.
    Ashworth B (1964) Preliminary trial of carisoprodol in multiple sclerosis. Practicioner 192: 540–542Google Scholar
  8. 8.
    Azouvi P, Mane M, Thiebaut JB, Denys P, Remy-Neris O, Bussel B (1996) Intrathecal baclofen administration for control of severe spinal spasticity: functional improvement and long-term follow-up. Arch Phys Med Rehabil 77: 35–39PubMedCrossRefGoogle Scholar
  9. 9.
    Baguley IJ, Nicholls JL, Felmingham KL, Crooks J, Gurka JA, Wade LD (1999) Dysautonomia after traumatic brain injury: a forgotten syndrome? J Neurol Neurosurg Psychiatry 67: 39–43PubMedGoogle Scholar
  10. 10.
    Barnes MP (2001) Medical management of spasticity in stroke. Age Ageing 30Suppl 1: 13–16PubMedGoogle Scholar
  11. 11.
    Barry MJ, VanSwearingen JM, Albright AL (2000) Intrathecal baclofen therapy and the role of the physical therapist. Ped Phy Ther 12: 77–86Google Scholar
  12. 12.
    Becker R, Alberti O, Bauer BL (1997) Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury. J Neurol 244: 160–166PubMedCrossRefGoogle Scholar
  13. 13.
    Becker R, Sure U, Petermeyer M, Bertalanffy H (1999) Continuous intrathecal baclofen infusion alleviates autonomic dysfunction in patients with severe supraspinal spasticity. J Neurol Neurosurg Psychiatry 66: 114–125PubMedGoogle Scholar
  14. 14.
    Becker R, Benes L, Sure U, Hellwig D, Bertallanfy H (2000) Intrathecal baclofen alleviates autonomic dysfunction in severe brain injury. J Clin Neurosci 7: 316–319PubMedCrossRefGoogle Scholar
  15. 15.
    Boeve BF, Wijdicks EFM, Benarroch EE, Schimdt KD (1998) Paroxysmal sympathetic storms (diencephalic seizures) after severe diffuse axonal head injury. Mayo Clinics Proceedings 73: 148–152Google Scholar
  16. 16.
    Bohannon RW, Smith MB (1987) Inter rater reliability of a modified Ashworth Scale of muscle spasticity. Phys Ther 67: 206–207PubMedGoogle Scholar
  17. 17.
    Boviatsis E, Kouyialis AT, Korfias S, Sakas DE (2005) Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg 107: 289–295PubMedCrossRefGoogle Scholar
  18. 18.
    Bowery NG (1993) GABA B receptor pharmacology. Annu Rev Pharmacol Toxicol 33: 109–147PubMedGoogle Scholar
  19. 19.
    Bowery NG, Bettler B, Froestl W, Gallagher JP, Marshall F, Raiteri M, Bonner TI, Enna SJ (2002) International Union of Pharmacology. XXXIII. Mammalian gamma-aminobutyric acid (B) receptors: structure and function. Pharmacol Rev 54: 247–264PubMedCrossRefGoogle Scholar
  20. 20.
    Burns AS, Meythaler J (2001) Intrathecal baclofren in tetraplegia of spinal origin: efficacy for upper extremity hypertonia. Spinal Cord 39: 413–419PubMedCrossRefGoogle Scholar
  21. 21.
    Campbell SK, Almeida GL, Penn RD, Corcos DM (1995) The effects of intrathecally administered baclofen on function in patients with spasticity. Phys Ther 75: 352–362PubMedGoogle Scholar
  22. 22.
    Carswell A, McColl MA, Baptiste S, Law M, Polatajko H, Pollock N (2004) The Canadian occupational performance measure: a research and clinical literature review. Can J Occup Ther 71: 210–222PubMedGoogle Scholar
  23. 23.
    Coffrey RJ, Edgar TS, Francisco GE, Graziani V, Meythaler JM, Ridgely PM, Sadiq SA, Turner MS (2002) Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 83: 735–741CrossRefGoogle Scholar
  24. 24.
    Cuny E, Richrer E, Castel JP (2001) Dysautonomia syndrome in the acute recovery phase after traumatic brain injury: relief with intrathecal baclofen therapy. Brain Inj 15: 917–925PubMedCrossRefGoogle Scholar
  25. 25.
    Dones I (2006) Intrathecal baclofen for the treatment of spasticity: selection criteria, management and efficacy in the wheel-chaired and bedridden versus the mobile patients. Acta Neurochir Suppl (in press)Google Scholar
  26. 26.
    Dykstra DD, Mendez A, Chappuis D, Baxter T, DesLauriers L, Stuckey M (2005) Treatment of cervical dystonia and focal hand dystonia by high cervical continuously infused intrathecal baclofen: a report of two cases. Arch Phys Med Rehabil 86: 830–833PubMedCrossRefGoogle Scholar
  27. 27.
    Dykstra D, Stuckey M, DesLauries L, Chappuis D, Krach L (2006) Intrathecal baclofen in the treatment of spasticity: indications, selection criteria, management and outcome in the adult versus the pediatric population. Acta Neurochir Suppl (in press)Google Scholar
  28. 28.
    Fann S (1988) Concept and classification of dystonia. Adv Neurol 50: 1–8Google Scholar
  29. 29.
    Fox S, Krnjevic K, Morris ME, et al (1978) Action of baclofen on mammalian synaptic transmission. Neuroscience 3: 495–515PubMedCrossRefGoogle Scholar
  30. 30.
    Francisco GE (2001) Can intrathecal baclofen therapy unleash functional recovery after stroke? Stroke 32: 2108–2109Google Scholar
  31. 31.
    Gatscher S, Becker R, Uhle E, Bertalanffy H (2002) Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentation pain. Acta Neurochir Suppl 79: 75–76PubMedGoogle Scholar
  32. 32.
    Gerszten PC, Albright AL, Johnstone GF (1998) Intrathecal baclofen infusion and subsequent orthopedic surgery in patients with spastic cerebral palsy. J Neurosurg 88: 1009–1013PubMedCrossRefGoogle Scholar
  33. 33.
    Gianino JM, York MM, Paice JA, Shott S (1998) Quality of life: effect of reduced spasticity from intrathecal baclofen. J Neurosci Nurs 30: 47–54PubMedGoogle Scholar
  34. 34.
    Grabb PA, Guin-Renfroe S, Meythaler JM (1999) Midthoracic catheter tip placement for intrathecal baclofen administration in children with quadriparetic spasticity. Neurosurgery 45: 833–836PubMedCrossRefGoogle Scholar
  35. 35.
    Grades JM, Nance P, Elovic E, McGuire J, Simpson DM (1997) Traditional pharmacological treatments for spasticity. Part III: General and regional treatments. Muscle Nerve Suppl 6: S92–S120Google Scholar
  36. 36.
    Guillaume D, Van Havenbergh A, Vloeberghs M, Vidal J, Roeste G (2005) A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. Arch Phys Med Rehabil 86: 2165–2171PubMedCrossRefGoogle Scholar
  37. 37.
    Hagglund G, Andersson S, Duppe H, Pedertsen HL, Nordmark E, Westbom L (2005) Prevention of severe contractures might replace multilevel surgery in cerebralpalsy: results of a population-based health care programme and new techniques to reduce spasticity. J Pediatr Orthop B 14: 269–273PubMedGoogle Scholar
  38. 38.
    Herman RM, D’Luzansky JC, Ippolito R (1992) Intrathecal baclofen suppresses central pain in patients with spinal lesions. Clin J Pain 8: 338–345PubMedGoogle Scholar
  39. 39.
    Horn TS, Yablon SA, Stokic DS (2005) Effect of intrathecal baclofen bolus injection on temporospatial gait characteristics in patients with acquired brain injury. Arch Phys Med Rehabil 86: 1127–1133PubMedCrossRefGoogle Scholar
  40. 40.
    Ivanhoe CB, Reistetter TA (2004). Spasticity: the misunderstood part of the upper motor neuron syndrome. Am J Phys Med Rehabil 83[Suppl]: S3–S9PubMedCrossRefGoogle Scholar
  41. 41.
    Kendal DA, Browner M, Emma SJ (1982) Comparison of the antinoceceptive effect of gamma-aminobutyric acid (GABA) agonists: evidence for a cholinergic involvement. J Pharmacol Exp Therap 220: 482–487Google Scholar
  42. 42.
    Kroin JS, Penn RD (1991) Cerebrospinal fluid pharmacokinetics of lumbar intrathecal baclofen. In: Lakke JPWF, Delhaas EM, Rutgers AWE (eds) Parenteral drug therapy in spasticity and Parkinson’s disease. Parthenon Publishing, Canforth UK, pp 73–83Google Scholar
  43. 43.
    Kroin J, Ali A, York M, Penn RD (1993) The distribution of medication along the spinal canal after chronic intrathecal administration. Neurosurgery 33: 226–230PubMedCrossRefGoogle Scholar
  44. 44.
    Kyriagis M, Grattan-Smith P, Scheinberg A, Teo C, Nakaji N, Waugh M (2004) Status dystonicus and Hallervorden-Spatz disease: treatment with intrathecal baclofen and pallidotomy. J Paediatr Child Health 40: 322–325PubMedCrossRefGoogle Scholar
  45. 45.
    Lance JW (1980) Symposium Synopsis. In: Feldman RG, Young RR, Kellas WP (eds) Spasticity, disordered motor control. Year Book Medical Publishers, CIBA-GEIGY Corporation, Chicago, pp 485–494Google Scholar
  46. 46.
    Law M, Baptiste S, McColl MA, Opzoomer A, Polatajko H, Pollock N (1990) The Canadian occupational performance measure: an outcome measure for occupational therapy. Can J Occup Ther 57: 82–87PubMedGoogle Scholar
  47. 47.
    Levy RA, Proudfit HK (1979) Analgesia produced by microinjection of balcofen and morphine at brainstem sites. Eur J Pharmacol 57: 43–55PubMedCrossRefGoogle Scholar
  48. 48.
    Lind G, Meyerson BA, Winter J, Linderoth B (2004) Intrathecal baclofen as adjuvant therapy to enhance the effect of spinal cord stimulation in neuropathic pain: a pilot study. Eur J Pain 8: 377–383PubMedCrossRefGoogle Scholar
  49. 49.
    Lind G, Schechtmann G, Winter J, Linderoth B (2006) Drugenhanced spinal stimulation for pain: a new strategy. Acta Neurochir Suppl (in press)Google Scholar
  50. 50.
    Loubser PG, Akman NM (1996) Effects of intrathecal baclofen on chronic spinal cord injury pain. J Pain Symptom Manage 12: 241–247PubMedCrossRefGoogle Scholar
  51. 51.
    Marquardt G, Lorenz R (1999) Intrathecal baclofen for intratable spasticity in amyotrophic lateral sclerosis. J Neurol 246: 619–620PubMedCrossRefGoogle Scholar
  52. 52.
    Marquardt G, Seifert V (2002) Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 72: 275–276PubMedCrossRefGoogle Scholar
  53. 53.
    Mayer NH (2002) Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motor neuron lesion. In: Mayer NH, Simpson DM (eds) Spasticity: etiology, management and the role of botulinum toxin. We Move, New York, pp 1–11Google Scholar
  54. 54.
    Medtronic (The) (2002) ITB Therapy Clinical Reference Guide for Spasticity Management UC19961184cEN NP 2584c, Medtronic, IncGoogle Scholar
  55. 55.
    Meythaler JM, Steers WD, Tuel SM, Cross LL, Haworht CS (1992) Continuous intrathecal baclofen in spinal cord spasticity. A prospective study. Am J Phys Med Rehabil 71: 321–327PubMedCrossRefGoogle Scholar
  56. 56.
    Meythaler JM, Steers WD, Tuel SM, Cross LL, Sesco DC, Haworth CS (1992) Intrathecal baclofen in hereditary spastic paraparesis. Arch Phys Med Rehabil 73: 794–797PubMedGoogle Scholar
  57. 57.
    Meythaler JM, Devivo JH, Hadely M (1996) Prospective study on the use sof bolus intrathecal baclofen for spastic hypertonia due to acquired brain injury. Arch Phys Med Rehabil 77: 461–466PubMedCrossRefGoogle Scholar
  58. 58.
    Meythaler JM, Guin-Renfroe S, Grabb P, Hadley MN (1999) Long-term continuously infused intrathecal baclofen for spastic-dystonic hypertonia in traumatic brain injury: 1-year experience. Arch Phys Med Rehabil 80: 13–19PubMedCrossRefGoogle Scholar
  59. 59.
    Meythaler JM, Guin-Renfroe S, Hadley MN (1999) Continuously infused intrathecal baclofen for spastic=dystonic hemiplegia: a preliminary report. Am J Phys Med Rehabil 78: 247–254PubMedCrossRefGoogle Scholar
  60. 60.
    Meythaler JM, Guin-Renfroe S, Brunner RC, Hadley MN (2001) Intrathecal baclofen for spastic hypertonia from stroke. Stroke 32: 2099–2109PubMedGoogle Scholar
  61. 61.
    Meythaler JM, Guin-Renfroe S, Law C, Grabb P, Hadely MN (2001) Continuously infused intrahtecal baclofen over 12 months for spastic hyperTonia in adolescents and adults with cerebral palsy. Arch Phys Med Rehabil 81: 155–161CrossRefGoogle Scholar
  62. 62.
    Middleton JW, Siddell PJ, Walker S, Molloy AR, Rutkowski SB (1996) Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil 77: 824–826PubMedCrossRefGoogle Scholar
  63. 63.
    Molteni F, Carda S, Cazzaniga M, Magoni L, Rossini M, Caimmi M (2005) Instrumental evaluation of gait modifications before and during intrathecal baclofen therapy: a 2-year follow-up case study. Am J Phys Med Rehabil 84: 303–306PubMedCrossRefGoogle Scholar
  64. 64.
    Murphy NA, Irwin MCN, Hoff C (2002) Intrathecal baclofen therapy in children with cerebral palsy: efficacy and complications. Arch Phys Med Rehabil 83: 1721–1725PubMedCrossRefGoogle Scholar
  65. 65.
    Ochs G, Struppler A, Meyerson BA, Linderoth B, Gybels J, Gardner BP, Teddy P, Jamous A, Weinmann P (1989) Intrathecal baclofen for long-term treatment of spasticity: a multicenter study. J Neurol Neurosurg Psychiatry 52: 933–939PubMedCrossRefGoogle Scholar
  66. 66.
    Ordia JI, Fischer E, Adamski E, Chagnon KG, Spatz EL (2002) Continuous intrathecal baclofen infusion by a programmable pump in 131 consecutive patients with severe spasticity of spinal origin. Neuromodulation 5: 16–24CrossRefGoogle Scholar
  67. 67.
    Penn R, Kroin JS (1984) Intrathecal baclofen alleviates spinal cord spasticity [letter]. Lancet 1: 1078PubMedCrossRefGoogle Scholar
  68. 68.
    Penn R, Kroin JS (1985) Continuous intrathecal baclofen for severe spasticity. Lancet 2: 125–127PubMedCrossRefGoogle Scholar
  69. 69.
    Penn RED, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, Kroin JS (1989) Intrathecal baclofen for severe spinal spasticity. N Engl J Med 320: 1517–1521PubMedGoogle Scholar
  70. 70.
    Petropoulou K, Panourias IG, Rapidi CA, Sakas DE (2006) The importance of neurorehabilitation to the outcome of neuromodulation in spasticity. Acta Neurochir Suppl (in press)Google Scholar
  71. 71.
    Petropoulou K, Panourias IG, Rapidi CA, Sakas DE (2006) The phenomenon of spasticity: a pathophysiological and clinical introduction to neuromodulation therapies. Acta Neurochirurgica Suppl (in press)Google Scholar
  72. 72.
    Plassat R, Perrouin Verbe B, Menei P, Menegalli D, Mathe JF, Richard I (2004) Treatment of spasticity with intrathecal baclofen administration: long-term follow-up, review of 40 patients. Spinal Cord 42: 686–693PubMedCrossRefGoogle Scholar
  73. 73.
    Pohl M, Rockstroh G, Ruckriem S, Mehrholz J, Pause M, Koch R, Strik H (2003) Time course of the effect of a bolus dose of intrathecal baclofen on severe cerebral spasticity. J Neurol 250(10): 1195–1200PubMedCrossRefGoogle Scholar
  74. 74.
    Remy-Neris O, Tiffreau V, Bouilland S, Bussel B (2003) Intrathecal baclofen in subjects with spastic hemiplegia: assessment of the antispastic effect during gait. Arch Phys Med Rehabil 84: 643–650PubMedCrossRefGoogle Scholar
  75. 75.
    Ridley B (2006) Intrathecal baclofen therapy: challenges in patients with multiple sclerosis. Rehabil Nurs 31: 158–164PubMedGoogle Scholar
  76. 76.
    Saitoh K, Konish S, Otsuka M (1975) Antagonism between lioresal and substance P in rat spinal cord. Brain Res 97: 177–180CrossRefGoogle Scholar
  77. 77.
    Sallerin B, Lazorthes Y (2003) Intrathecal baclofen. Experimental and pharmacokinetic studies. Neurochirurgie 49: 271–275PubMedGoogle Scholar
  78. 78.
    Sawynok J, Reid A (1986) Role of ascending and descending noradrenergic pathways in the antinociceptive effect of baclofen and clonidine. Brain Res 386: 341–350PubMedCrossRefGoogle Scholar
  79. 79.
    Shakespeare DT, Boggild M, Young C (2001) Anti-spasticity agents for multiple sclerosis. Cocbrane Databse Syst Rev, CD001332Google Scholar
  80. 80.
    Silbert PL, Matsumoto JY, McManis PG, Stolp-Smith KA, Elliott BA, McEvoy KM (1995) Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology 45: 1893–1897PubMedGoogle Scholar
  81. 81.
    Sitaram BR, Tsui M, Rawicki HB, Sitaram M (1997) Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine. Int J Pharmaceutics 153: 13–24CrossRefGoogle Scholar
  82. 82.
    Slonimski M, Abram SE, Zuniga RE (2004) Intrathecal baclofen in pain management. Reg Anesth Pain Med 29: 269–276PubMedCrossRefGoogle Scholar
  83. 83.
    Smail DB, Jacq C, Denys P, Bussel B (2005) Intrathecal baclofen int eh treatment of painful, disabling spasms in Friedreich’s ataxia. Mov Disord 20: 758–759PubMedCrossRefGoogle Scholar
  84. 84.
    Stempien L, Tsai T (2000) Intrathecal baclofen pump use for spasticity. Am J Phys Med Rehabil 79: 536–541PubMedCrossRefGoogle Scholar
  85. 85.
    Taira T, Hori T (2006) Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. Acta Neurochir Suppl (in press)Google Scholar
  86. 86.
    Taira T, Kawamura H, Tanikawa T, Iseki H, Kawabatake H, Takakura K (1995) A new approach to control central deafferentiation pain: Spinal intrathecal baclofen. Stereotactic Funct Neurosurg 65: 101–105CrossRefGoogle Scholar
  87. 87.
    Takenaka K, Sasaki S, Nakamura K, Uchida A, Fujita H, Itoh H, Nakata T, Takeda K, Nakagawa M (1995) Hypothalamic and medullary GABAA and GABAB-ergic systems differently regulate sympathetic and cardiovascular systems. Clin Exp Pharmacol Physiol Suppl 22: S48–S50PubMedGoogle Scholar
  88. 88.
    Tsui M, Lam S (1992) Stability of intrathecal baclofen and morphine (Letter). Aust J Hosp Pharm 22: 258Google Scholar
  89. 89.
    Turner MS (2003) Early use of intrathecal baclofen in brain injury in pediatric patients. Acta Neurochir Suppl 87: 81–83PubMedGoogle Scholar
  90. 90.
    van Hilten BJ, van de Beek WJ, Ho JI, Voormolen JH, Delhaas EM (2000) Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. N Engl J Med 343: 625–630PubMedCrossRefGoogle Scholar
  91. 91.
    Vasconcelos OM, Dalakas MC (2003) Stiff-person syndrome. Curr Treat Options Neurol 5: 79–90PubMedGoogle Scholar
  92. 92.
    Vatine JJ, Magora F, Swissa A, Magora A (1989) Effect of intrathecal baclofen in low back pain with root compression symptoms. Pain Clin 2: 207–217Google Scholar
  93. 93.
    Vloeberghs M (2002) Intrathecal baclofen in the management of spasticity due to cerebral palsy. Adv Clin Neurosci Rehabil 2: 11–13Google Scholar
  94. 94.
    Walker RH, Danisi FO, Swope DM, Goodman RR, Germano IM, Brin MF (2000) Intrathecal baclofen for dystonia: benefits and complications during six years of experience. Mov Disord 15: 1242–1247PubMedCrossRefGoogle Scholar
  95. 95.
    Wilson P, Yaksh TL (1978) Baclofen is antinociceptive in the spinal intrathecal space of animals. Eur J Pharmacology 51: 323–320CrossRefGoogle Scholar
  96. 96.
    Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS (2004) Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 75: 1553–1557PubMedCrossRefGoogle Scholar
  97. 97.
    Zhang SJ, Jackson MB (1993) GABA-activated chloride channels in secretory nerve endings. Science 259: 531–534PubMedCrossRefGoogle Scholar
  98. 98.
    Zuniga RE, Schlicht CR, Abram SE (2000) Intrathecal baclofen is analgesic in patients with chronic pain. Anesthesiology 92: 876–880PubMedCrossRefGoogle Scholar
  99. 99.
    Zuniga RE, Perera S, Abram SE (2002) Intrathecal baclofen; a useful agent in the treatment of well-established complex regional pain syndrome. Reg Anesth Pain Med 27: 90–93PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • I. G. Panourias
    • 1
  • M. Themistocleous
    • 1
  • Damianos E. Sakas
    • 1
  1. 1.P. S. Kokkalis Hellenic Center for Neurosurgical ResearchAthensGreece

Personalised recommendations